Pattern of HCV antibodies with special reference to NS5A reactivity in HCV-infected patients: relation to viral genotype, cryoglobulinemia and response to interferon

被引:21
|
作者
Frangeul, L
Cresta, P
Perrin, M
Duverlie, G
Khorsi, H
Musset, L
Opolon, P
Huraux, JM
Lunel, F
机构
[1] CHU Pitie Salpetriere, Serv Virol, F-75651 Paris 13, France
[2] CHU Pitie Salpetriere, Serv Hepatogastroenterol, F-75651 Paris, France
[3] CHU Pitie Salpetriere, Serv Immunochim, F-75651 Paris 13, France
[4] CHU Hop Sud, Serv Virol, Amiens, France
[5] Hop Angers, Serv Bacteriol Virol, Angers, France
关键词
anti-HCV antibodies; cryoglobulinemia; hepatitis C virus; interferon; interferon sensitivity determining region (ISDR); NS5A;
D O I
10.1016/S0168-8278(98)80275-4
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: We aimed to compare the antihepatitis C virus reactivity in confirmatory assays (RIBA 3.0 (C)Ortho Diagnostic and INNO-LIA HCV Ab III (C)Innogenetics) among patients infected with different hepatitis C virus genotypes, with or without cryoglobulinemia, and in patients treated with interferon, Methods: One hundred and three patients followed in our hepatogastroenterology unit were included in the study and compared to 320 consecutive patients tested using RIBA 3.0, Seventy-nine of the 103 patients were treated,vith interferon. Long-term responders to interferon were defined as having normal alanine aminotransferase levels and being HCV RNA negative 6 months after the end of treatment, Initial responders mere defined as having normal alanine aminotransferase levels at the end of interferon therapy but abnormal alanine aminotransferase levels and/or detectable HCV RNA during the following 6 months. Non-responders mere defined as still having elevated alanine aminotransferase during and after interferon, Serological tests (RIBA and INNO-LIA) were performed according to the manufacturers' instructions. HCV RNA was detected by nested polymerase chain reaction. Hepatitis C virus genotype was determined by using a Line Probe Assay ((C)Innogenetics). Results: There was no significant difference in the pattern of hepatitis C virus reactivity according to the hepatitis C virus genotype or presence of cryoglobulinemia. Twenty-three patients were classified as nonresponders, 35 as initial responders, 21 as long-term responders, NS5 reactivity was significantly different (p<0.01) between these three groups: 34% of non-responders (8/23) had RIBA 3.0 NS5 reactivity and 13% (3/23) were reactive in the INNO-LIA III. Almost all long-term responders (95%) had NS5 reactivity by both RIBA 3.0 and INNO-LIA III. Conclusion: We conclude that patients who respond to interferon have stronger reactivity against NS5 antigens than non-responders, Molecular changes in the NS5A region may be responsible for such differences, as recently suggested.
引用
收藏
页码:538 / 543
页数:6
相关论文
共 37 条
  • [21] Randomized controlled trial of the NS5A inhibitor daclatasvir plus pegylated interferon and ribavirin for HCV genotype-4 (COMMAND-4)
    Hezode, Christophe
    Alric, Laurent
    Brown, Ashley
    Hassanein, Tarek
    Rizzetto, Mario
    Buti, Maria
    Bourliere, Marc
    Thabut, Dominique
    Molina, Esther
    Rustgi, Vinod
    Samuel, Didier
    McPhee, Fiona
    Liu, Zhaohui
    Yin, Philip D.
    Hughes, Eric
    Treitel, Michelle
    ANTIVIRAL THERAPY, 2016, 21 (03) : 195 - 205
  • [22] Detection of HCV RNA and NS5A Protein in Peripheral Blood Mononuclear Cells After Sustained Virological Response May Cause Viral Relapse
    Zaman, Nasib
    Asad, Muhammad Javaid
    Raza, Abida
    Raja, Ghazala Kaukab
    Akhter, Shamim
    Mahmood, Majid
    Mahmood, Raja Tahir
    PAKISTAN JOURNAL OF ZOOLOGY, 2015, 47 (04) : 981 - 987
  • [23] The presence of multiple NS5A RASs is associated with the outcome of sofosbuvir and ledipasvir therapy in NS5A inhibitor-naive patients with chronic HCV genotype 1b infection in a real-world cohort
    Kozuka, R.
    Hai, H.
    Motoyama, H.
    Hagihara, A.
    Fujii, H.
    Uchida-Kobayashi, S.
    Morikawa, H.
    Enomoto, M.
    Murakami, Y.
    Kawada, N.
    Tamori, A.
    JOURNAL OF VIRAL HEPATITIS, 2018, 25 (05) : 535 - 542
  • [24] The genotype CC of IL-28BSNP rs12979860 is significantly associated with a sustained virological response in chronic HCV-infected Pakistani patients
    Khubaib, Bushra
    Saleem, Sana
    Idrees, Muhammad
    Afzal, Samia
    Wasim, Muhammad
    JOURNAL OF DIGESTIVE DISEASES, 2015, 16 (05) : 293 - 298
  • [25] Mutations in the NS5A region do not predict interferon-responsiveness in American patients infected with genotype 1b hepatitis C virus
    Chung, RT
    Monto, A
    Dienstag, JL
    Kaplan, LM
    JOURNAL OF MEDICAL VIROLOGY, 1999, 58 (04) : 353 - 358
  • [26] Assessment of interleukin 28B genotype as a predictor of response to combined therapy with pegylated interferon plus ribavirin in HCV infected Egyptian patients
    Fathy, Mona M.
    Taleb, Mohamed E. Abo
    El Hawary, Mohamed S.
    Nabih, Mona I.
    Aref, Wael M.
    Makhlouf, Manal M.
    CYTOKINE, 2015, 74 (02) : 268 - 272
  • [27] Genetic variability in the 5′ UTR and NS5A regions of hepatitis C virus RNA isolated from non-responding and responding patients with chronic HCV genotype 1 infection
    Araujo, Flavio M. G.
    Sonoda, Ivan V.
    Rodrigues, Nilton B.
    Teixeira, Rosangela
    Redondo, Rodrigo A. F.
    Oliveira, Guilherme C.
    MEMORIAS DO INSTITUTO OSWALDO CRUZ, 2008, 103 (06): : 611 - 614
  • [28] Mutations in the E2 and NS5A Regions in Patients Infected With Hepatitis C Virus Genotype 1a and Their Correlation With Response to Treatment
    Yahoo, Neda
    Sabahi, Farzaneh
    Shahzamani, Kiana
    Malboobi, Mohamad Ali
    Jabbari, Hossain
    Sharifi, Houshang
    Mousavi-Fard, Seyed Hossein
    Merat, Shahin
    JOURNAL OF MEDICAL VIROLOGY, 2011, 83 (08) : 1332 - 1337
  • [29] HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirin
    Abbate, I
    Lo Iacono, O
    Di Stefano, R
    Cappiello, G
    Girardi, E
    Longo, R
    Ferraro, D
    Antonucci, G
    Di Marco, V
    Solmone, M
    Craxì, A
    Ippolito, G
    Capobianchi, MR
    JOURNAL OF HEPATOLOGY, 2004, 40 (05) : 831 - 836
  • [30] Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort
    Alonso, S.
    Riveiro-Barciela, M.
    Fernandez, I.
    Rincon, D.
    Real, Y.
    Llerena, S.
    Gea, F.
    Olveira, A.
    Fernandez-Carrillo, C.
    Polo, B.
    Carrion, J. A.
    Gomez, A.
    Devesa, M. J.
    Baliellas, C.
    Castro, A.
    Ampuero, J.
    Granados, R.
    Pascasio, J. M.
    Rubin, A.
    Salmeron, J.
    Badia, E.
    Planas, J. M. M.
    Lens, S.
    Turnes, J.
    Montero, J. L.
    Buti, M.
    Esteban, R.
    Fernandez-Rodriguez, C. M.
    JOURNAL OF VIRAL HEPATITIS, 2017, 24 (04) : 304 - 311